Still, the few studies describing the development of modified GALC enzymes in basic and pre-clinical studies in GLD mice lack a comprehensive assessment of safety and efficacy in therapeutically relevant cell types, i.e., HSPCs and neural cells (Zhang et al., 2008; Hu et al., 2016; Pan et al., 2019). This evidence concerns the gene GALC and Krabbe disease.